Form 990 for tax year 2023

Totals

Total revenue

$1,451,316

Total expenses

$1,027,905

Contributions and grants received

$1,467,491

Grants paid

$300,000

Program service revenue

$0

Investment income

$13,201

Other revenue

-$29,376

Total assets, end of year

$3,781,783

Total liabilities, end of year

$14,196

Net assets or fund balances, end of year

$3,767,587

Program services expenses (Part IX)

$957,629

Management and general expenses

$61,093

Fundraising expenses

$9,183

Program service expenses (Part III)

$957,629

Program services were 93.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2023

• PATIENT NAVIGATION PROGRAMS, INCLUDING PATIENT PROGRAM SERVICES/RESEARCH ADVOCACY PROGRAMS/CANCER RESEARCH SERVICES OF WHICH 300,000 WAS AWARDED IN GRANTS TO INVESTIGATORS ASSOCIATED WITH OR COLLABORATING WITH ICAN'S INTERNATIONAL RESEARCH CONSORTIUM, INCLUDING THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS SOUTHWESTERN, THE UNIVERSITY OF PENNSYLVANIA, THE UNIVERSITY OF PITTSBURGH, AND THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. GRANTS WERE AWARDED FOR PROPOSALS RELATING TO MOLECULAR ALTERATIONS AND RESISTANCE MECHANISMS, DEVELOPMENT OF DRUGS WITH NEW MECHANISMS OF ACTION, DEVELOPMENT OF EARLY DETECTION ASSAYS, AND RESEARCH REGARDING LEPTOMENINGEAL DISEASE (LMD). THE 2023-2024 GRANT CYCLE WAS FUNDED BY ICAN'S SPECIAL EVENTS, INCLUDING THE ANNUAL FISTBUMP FUNDRAISER AND THE ANNUAL APPLIED UNDERWRITING GOLF TOURNAMENT AS WELL AS BY ICAN MEMORIAL AND TRIBUTE PROGRAMS. ICAN'S EXON 20 INTERNATIONAL RESEARCH CONSORTIUM CONSISTS OF TOP THORACIC RESEARCH ONCOLOGISTS AND SCIENTISTS WHO HAVE PRODUCED AN ARRAY OF TRANSFORMATIVE JOURNAL ARTICLES THAT ARE PROPELLING THE FIELD OF ACTIONABLE MUTATIONS FORWARD. ICAN'S PATIENT SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS. OUR PATIENTS, CARE PARTNERS, AND RESEARCH ADVOCATES REVIEW CLINICAL TRIAL CONCEPTS, PROTOCOLS, AND INFORMED CONSENT FORMS. THE ORGANIZATION'S ONCOLOGY NURSING SERVICES AND ANGEL BUDDIES/MET MENTORS (PEER-TO-PEER PATIENT AND CARE PARTNER ADVISORS) ASSIST PATIENTS AND THEIR FAMILIES WITH SIDE EFFECTS MITIGATION STRATEGIES THROUGHOUT CLINICAL TRIALS AND STANDARD TREATMENT. UNDER THE ICAN NONPROFIT UMBRELLA, ICAN MANAGES THE EXON 20 GROUP (EGFR EXON 20 WARRIORS/HER2 WARRIORS), THE MET CRUSADERS, THE BIOMARKER COLLABORATIVE, AND THE PD-L1 AMPLIFIEDS.

  Expenses $535,000 · Grants $300,000

• PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL ACCESS ISSUES RELATED TO UNDER- RESOURCED PATIENT COMMUNITIES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS FOR EXON 20 GROUP, MET CRUSADERS, BIOMARKER COLLABORATIVE, AND PAN-TUMOR ICAN PROGRAMS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND ABROAD. ICAN'S PUBLIC POLICY ADVOCACY EFFORTS WERE VIGOROUSLY PURSUED AT THE STATE AND FEDERAL LEVELS, INCLUDING ISSUES SUCH AS THE INFLATION REDUCTION ACT AND FIXING THE SMALL MOLECULE PENALTY; WEIGHING IN ON PRESCRIPTION DRUG AFFORDABILITY BOARDS; SUPPORTING PBM REFORM; SUPPORTING 340B PROGRAM REFORM; ADVOCATING THE PRESERVATION OF THE BAYH-DOLE PROGRAM; SUPPORTING BIOMARKER TESTING BILLS (PASSED IN 20 STATES AND COUNTING); SUPPORTING CO- PAY ACCUMULATOR AND REBATE REFORM BILLS (ACTIVE PARTICIPANT IN THE "ALL COPAYS COUNT COALITION"), AND OPPOSING STATE-LED EFFORTS THAT IMPEDE PATIENT ACCESS TO NOVEL THERAPEUTICS, SUCH AS STEP THERAPY/FAIL-FIRST THERAPY WHERE WE HAVE VIGOROUSLY OPPOSED THOSE ANTI-PATIENT PRACTICES SINCE 2012.

  Expenses $214,650

• MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES: 1) ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND EDUCATING THEM ABOUT THE ARRAY OF MOLECULAR PROFILING TECHNOLOGIES THAT CAN EITHER BE ACCESSED BY PATIENTS AND/OR RESEARCHERS--DNA, RNA, AND THUS MULTI-OMICS: GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, METHYLATION, IMMUNE CELL STUDIES, AND SO FORTH; 2) REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS; 3) CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED, WITH THE INPUT OF MEMBERS OF ICAN'S BIOMARKERS COUNCIL, PHYSICIANS COUNCIL, AND DRUG DEVELOPMENT COUNCIL; 4) EDUCATING PATIENTS ABOUT MOLECULAR TUMOR BOARDS (E.G. TARGET CANCER'S TRACK STUDY, ASCO TAPUR STUDY; ROCHE NAVIFY); AND, 5) CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN-TUMOR/PAN- HEME/PAN-RARE CANCER BASIS IF AN APPROPRIATE CLINICAL TRIAL IS A MOLECULAR MATCH. ICAN AND ITS SUPPORT GROUPS ARE ALSO ENGAGED IN THE AREAS OF DECENTRALIZING TRIALS; "JUST-IN-TIME" TRIALS; AND EXPEDITING THE TRANSFER OF PATIENTS FROM ONE CLINICAL TRIALS SITE (MID-REGIMEN) TO ANOTHER MORE CONVENIENT SITE (U.S. TO U.S. OR EU TO U.S.). ICAN, THE EXON 20 GROUP, AND THE MET CRUSADERS SPECIALIZE IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. THE BIOMARKER COLLABORATIVE 1) CONNECTS PATIENTS TO BOTH THE APPROPRIATE SPECIFIC BIOMARKER SUPPORT GROUP AND THE RELEVANT GENERAL ORGANIZATIONS THAT COVER THE PATIENT'S SPECIFIC CANCER TYPE; AND 2) EDUCATES PATIENTS ABOUT THEIR DRIVER MUTATION, AMPLIFICATION OR FUSION (IF IDENTIFIED BY THE RELEVANT LABORATORY'S REPORT) AS WELL AS THEIR GENE CO-ALTERATIONS. ICAN AND ITS SUPPORT ORGANIZATIONS EACH STRESS THE IMPORTANCE OF MULTI-STAKEHOLDER COLLABORATIONS WITH RESEARCH ADVOCATES, PATIENT ADVOCATES, COMMUNITY ADVOCATES, CLINICIANS, AND SCIENTISTS.

  Expenses $207,979

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

• SHERRY WEINSTEIN

  CHAIR-TTEES-

  Total calculated

  $0

  Hours/week

  30

• MARCIA K HORN JD

  PRESIDENT AN

  Total calculated

  $199,531

  From this org

  $172,000

  From related orgs

  $0

  Other

  $27,531

  Hours/week

  90

  Schedule J breakdown matched by us

  Base

  $172,000

  Bonus

  —not reported

  Other

  —not reported

  Deferred

  —not reported

  Nontaxable benefits

  $27,531

  Filer's total

  $199,531

• CATHY DALZELL

  CHAIR ADIVIS

  Total calculated

  $0

  Hours/week

  10

• CHERYL J HINTZEN-GAINES

  CHAIR-HONORA

  Total calculated

  $0

  Hours/week

  3

• SIDNEY M ROSEN ESQ

  FOUNDING CHA

  Total calculated

  $0

  Hours/week

  10

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• HEYMACH LAB-MD ANDERSON CANCER CNTR

  $100,000

  ACTIONABLE MUTATIONS

• JOHN MINNA LAB-UT SOUTHWESTERN LABS

  $70,000

  ACTIONABLE MUTATIONS

• O'CONNOR LAB-CNTR CELLULAR IMMUNO

  $52,500

  IMMUNOTHERAPY RESRCH

• TIMOTHY BURNS LAB-UNIV PITTSBURGH

  $40,000

  ACTIONABLE MUTATIONS

• LUNG CANCER RESEARCH FOUNDATION

  $37,500

  UCSF GRANT

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• BIOMARKER COLLABORATIVE INC

  501C3 · SUPPORT · WI

  Directly controlled by INTERNATL CANCER ADVOCACY NETWORK

• MET CRUSADERS INC

  503C3 · SUPPORT · WI

  Directly controlled by INTERNATL CANCER ADVOCACY NETWORK

Provenance

Return type

form_990

Tax year

2023

Filed

15 November 2024

IRS schema version

2023v5.0

Source object

202413209349313671

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.